ceftazidime, Glaxo; ceftriaxone, Roche, Basel, Switzerland; imipenem, Merck Sharp & Dohme; chloramphenicol, Chong Kun Dang Co., Seoul, Korea; clindamycin, The Upjohn Co., Kalamazoo, Mich.; metronidazole, Shinkeeorug, Hong Kong; and tetracycline, Chong Kun Dang Co.
Antimicrobial susceptibility testing was performed by an agar dilution method (18) . Antimicrobial dilutions ranged from 256 to 0.063 ,ug/ml, except for imipenem, which was tested at 256 to 0.03 ,ug/ml. An ,ug/ml, respectively, and we detected no resistance. Cefoxitin was the second most active, with an MIC50 and an MIC90 of 8 and 32 ,ug/ml, respectively, and an 6% resistance rate at the breakpoint. Piperacillin, ticarcillin, cefotetan, cefotaxime, and ceftriaxone were less active and had resistance rates of 21, 25, 28, 33, and 36%, respectively. More frequently, resistance was found to ceftazidime, cefamandole, penicillin G, and tetracycline. No isolates were found to be resistant to metronidazole or chloramphenicol. The MIC50 and MIC9Q of clindamycin were 0.5 and >256 ,ug/ml, respectively, and the resistance rate was 24%.
There was variability in resistance rates among the various species of the B. fragilis group for some drugs ( Table 2) . Among the various species in the group, B. fragilis was more often susceptible to the beta-lactam drugs, and B. distasonis was more often resistant.
The results of this study indicate that there were marked differences in the in vitro activities of the currently available beta-lactam drugs against the B. fragilis group organisms. Imipenem was the most active beta-lactam drug and had similar activities against all species of the B. fragilis group. Cefoxitin was the second most active and showed some resistance variability by species, with B. distasonis most frequently displaying resistance (17%). These results are in agreement with those of published surveys (1, 5). P-Lactamases are produced by a majority of resistant isolates of the B. fragilis group (16, 21) . In general, resistance to beta-lactam drugs in the B. fragilis group is the result of 1-lactamase inactivation of the drugs. The good activities of imipenem and cefoxitin are probably due to the resistance of the drugs to ,B-lactamases (6, 7, 17, 19, 20) . The rates of resistance to piperacillin, ticarcillin, and cefotetan were slightly higher than those observed in other studies (2, 5) . Cefotetan, ceftriaxone, and cefotaxime showed the highest variations in activities against the species of the B. fragilis group. The cefotetan resistance rate was lowest with B. fragilis (6%) and highest with B. distasonis (100%). As expected, to ceftazidime, cefamandole, penicillin G, and tetracycline the rates of resistance were higher, and these drugs should not be considered for the treatment of infections involving organisms of the B. fragilis group.
Chloramphenicol and metronidazole were the most active non-beta-lactam drugs, and to these no resistant isolates were found. The rate of resistance to clindamycin, 24%, was similar to those found by Betriu et al. (1) and Finegold and Wexler (11) but was higher than those found in other studies (2, 5, 8) . Clindamycin displayed poor activity against the non-B. fragilis species of the B. fragilis group.
These results emphasize the usefulness of periodic susceptibility studies of anaerobic bacteria in each country and the need for further investigations to demonstrate changes in susceptibility patterns.
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